Validation of a health-related quality of life questionnaire in patients with recurrent Clostridioides difficile infection in ECOSPOR III, a Phase 3 randomized trial.

Brittany R LapinKevin W GareyHenry WuV SissiShirley P HuangPat Ray ReeseElaine WangAbhishek Deshpande

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022)

Cdiff32 is a valid, reliable, and responsive disease-specific HRQOL questionnaire fit-for-purpose for interventional treatment trials. The significant improvement in non-recurrent patients by 8 weeks demonstrates the negative impact of rCDI on HRQOL.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
patient reported
cross sectional
clostridium difficile
peritoneal dialysis
prognostic factors
patient reported outcomes
drug delivery
replacement therapy